Analystreport

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) had its price target raised by analysts at Canaccord Genuity from $9.00 to $15.00. They now have a "buy" rating on the stock.

Zynerba Pharmaceuticals, Inc.  (ZYNE) 
Last zynerba pharmaceuticals, inc. earnings: 3/10 06:50 am Check Earnings Report
US:NASDAQ Investor Relations: ir.zynerba.com